Andere talen Vicore Pharma Holding AB

Aandelen

VICO

SE0007577895

Beurs gesloten - Nasdaq Stockholm Andere beurzen 17:29:53 23-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
17,44 ^SEK	+2,95%		+5,44%	+22,99%

04/04	Vicore Pharma Holding AB (Publ) kondigt aan dat Maarten Kraan zich als bestuurslid niet herkiesbaar heeft gesteld	CI
19/03	Vicore kondigt FDA Breakthrough Device Designation aan voor AlmeeTM, een digitale therapie voor patiënten met longfibrose	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Vicore to Present at Upcoming April 2024 Investor Conferences	15/04
Vicore to Present at Upcoming Investor Conferences	15/04
Vicore to Present at Upcoming Investor Conferences	12/04
Vicore Pharma Holding AB Announces Maarten Kraan, as Board Member Declined Re-Election	04/04
Notice of annual general meeting of Vicore Pharma Holding AB (publ)	04/04
Vicore Announces Presentations at the 2024 American Thoracic Society International Conference	28/03
Vicore publishes the Annual Report for 2023	27/03
Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis	19/03
Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis	19/03
Year-end report 2023	28/02
Vicore Pharma Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Vicore Pharma Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Vicore to Present at Upcoming Investor Conferences	27/02
Vicore Pharma Signs Licensing Deal for Idiopathic Pulmonary Fibrosis Drug Candidate	09/02
Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan	09/02
Vicore to Present at Upcoming Investor Conferences	31/01
Alex Therapeutics and Vicore Pharma Announces Positive Results of the COMPANION Study	04/01
Alex Therapeutics Reports Positive Results from the Randomized-Controlled Trial of its Digital Therapy for Anxiety	04/01
Vicore Reports Positive Results for the Pivotal Study of its Digital Therapy for Patients with Pulmonary Fibrosis	04/01
Vicore Pharma Holding AB Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates	02/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Vicore Pharma Holding AB

Aandelen

VICO

SE0007577895

Andere talen

Filters